News Novartis to buy ophthalmology firm Encore Vision Swiss pharma buys treatment for common age-related vision problem.
News Novartis/Ophthotech eye combo fails in phase 3 Lucentis and pegpleranib combination misses goal in wet AMD.
News Regeneron to develop long release Eylea successor Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
News Shire launches potential blockbuster dry eye drug in US Xiidra could be ophthalmology blockbuster.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
